Third Arc Bio, a Boston, MA-based biotech company developing multifunctional antibodies, raised $165M in Series A funding.
The round was led by Vida Ventures and Cormorant Asset Management and Hillhouse Investment. Omega Funds continued also participated with additional investors including Goldman Sachs Alternatives, BVF Partners LP, funds and accounts advised by T. Rowe Price Associates, Inc., Janus Henderson Investors, funds managed by abrdn Inc., Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, and AbbVie Ventures.
The company intends to use the funds to advance its clinical studies to address needs in oncology and autoimmunity.
Led by CEO Peter Lebowitz, Third Arc Bio is a biotech company developing multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. Its drug development engine delivers biologics optimized to create T cell engagement by leveraging two technologies that empower a pipeline of high value therapeutics – a solid tumor synergy platform and an I&I platform that offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety.
The team includes:
- Sanjaya Singh
- Joe Erhardt
- Debi Watson
FinSMEs
23/07/2024